http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3137069-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e36dac65d20a28459d8ec287bc55ad7a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e5f29a562a18b2a76eff34b75ed844c1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f4f902388e563e167f2748fca8c76a75
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5123
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-192
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-192
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B82Y5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
filingDate 2014-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29551e5265d9e7264e1fb93396ef5403
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b9a3355558e23abcff59e21fb13b354
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5cca400af272c838d50231af7179df3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e2ff203ad6f34c0866289d59cee4ee90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afda22c8dd14a338b7da3238774c7f76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_decb2d8f87282d60defe49d155f0fbd0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_acf32a2cbf18277dd1027b31dcf7eda3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_042f503621b66a27ddd21594f76045cf
publicationDate 2017-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-3137069-A1
titleOfInvention Nanoparticle formulation containing farnesylthiosalicylic acid (salirasib)
abstract It is related to farnesylthiosalicylic acid (Salirasib, FTA) loaded PLGA nanoparticles functionalized with lipid/cationic lipid-PEG (hybrid), which can cross the BBB in effective concentration. The formulations can be administered intravenously or intratumorally.
priorityDate 2014-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226513297
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID389644

Total number of triples: 29.